Published in Clin Vaccine Immunol on December 18, 2013
Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology (2014) 0.82
Francisella tularensis Vaccines Elicit Concurrent Protective T- and B-Cell Immune Responses in BALB/cByJ Mice. PLoS One (2015) 0.80
Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity. Clin Vaccine Immunol (2017) 0.75
Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci (2007) 4.20
Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun (1991) 3.99
In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun (1992) 3.07
Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol (2006) 2.68
Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun (1996) 2.50
Innate and adaptive immunity to Francisella. Ann N Y Acad Sci (2007) 2.32
Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun (2005) 1.98
Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine (2001) 1.86
New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci (2007) 1.78
Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun (1994) 1.75
Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun (1999) 1.70
The structure and function of Francisella lipopolysaccharide. Ann N Y Acad Sci (2007) 1.64
Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol (2007) 1.61
Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J Med Microbiol (2003) 1.48
Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol Rev (2008) 1.48
Structure of the O-antigen of Francisella tularensis strain 15. Carbohydr Res (1991) 1.48
Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect Immun (1999) 1.36
Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. Proc Natl Acad Sci U S A (1994) 1.29
A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun (2007) 1.27
Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am J Med Sci (1994) 1.27
Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis. PLoS One (2010) 1.26
Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog (2003) 1.23
Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc Natl Acad Sci U S A (2000) 1.21
Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine (2008) 1.19
Tularemia pneumonia. Infect Dis Clin North Am (2010) 1.17
Francisella tularensis vaccines. Vaccine (2009) 1.11
Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol (2011) 1.11
Recognition of a carbohydrate antigenic determinant of Salmonella by an antibody. Biochem Soc Trans (1993) 1.07
Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett (2007) 1.06
Structural analysis of the O-antigen of Francisella tularensis subspecies tularensis strain OSU 10. J Med Microbiol (2005) 1.03
A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides. Biochemistry (2011) 0.98
Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide. Hybridoma (Larchmt) (2011) 0.90
Detection of Francisella tularensis-specific antibodies in patients with tularemia by a novel competitive enzyme-linked immunosorbent assay. Clin Vaccine Immunol (2012) 0.90
Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria. PLoS One (2013) 0.88
Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide. Biochemistry (2012) 0.86
Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia. Immunology (2012) 0.84
Community-acquired pneumonia in patients requiring hospitalization. Respirology (2001) 0.84
The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide. Immunology (2013) 0.82
The integrin-growth factor receptor duet. J Cell Physiol (2007) 1.75
Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng (2006) 1.10
Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett (2007) 1.06
A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides. Biochemistry (2011) 0.98
Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide. Hybridoma (Larchmt) (2011) 0.90
Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide. Biochemistry (2012) 0.86
Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage. Immunol Lett (2002) 0.86
Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia. Immunology (2012) 0.84
The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide. Immunology (2013) 0.82
Generation and preliminary characterization of an antibody library with preferential reactivity to human colorectal cancer cells as compared to normal human blood cells. Immunol Lett (2004) 0.81
Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity. Monoclon Antib Immunodiagn Immunother (2014) 0.77
Polyclonal Fab phage display libraries with a high percentage of diverse clones to Cryptosporidium parvum glycoproteins. Int J Parasitol (2003) 0.76
Antibody treatment of human tumor xenografts elicits active anti-tumor immunity in nude mice. Immunol Lett (2007) 0.75
Generation of anti-colorectal cancer fab phage display libraries with a high percentage of diverse antigen-reactive clones. Comb Chem High Throughput Screen (2002) 0.75
Expression of a prototypic anti-colorectal cancer polyclonal antibody library in mammalian cells. Immunol Lett (2003) 0.75